The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
REGULATORY
Tainted Moderna Jabs Run Afoul of PMD Law: Minister
The distribution of contaminated Moderna COVID-19 vaccines constitutes a violation of the Pharmaceuticals and Medical Devices (PMD) Law, Health Minister Norihisa Tamura said on September 15. “As to the vaccines in which the contamination was found this time, we could…
To read the full story
Related Article
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
- TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
- “Human Error” Is to Blame for Contamination of Moderna COVID-19 Vaccines: Report
October 4, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
September 9, 2021
- Post-Vaccination Death Cases Being Investigated with Integrity: Takeda
September 8, 2021
- Takeda Recalling Suspended Batches of Moderna Jabs in Japan; Administrative Action Possible
September 2, 2021
REGULATORY
- US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
March 19, 2025
- MHLW to Investigate Pharmaceutical Ad Regulations in US, Europe
March 18, 2025
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
- PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
March 17, 2025
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…